Stock

Kyverna Therapeutics, Inc. KYTX

$7.43+2.06%

All stocks Create account to unlock

Overview

KYTX market data

Price History

KYTX price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for KYTX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

8 captured

8-K filing — Kyverna Therapeutics, Inc. (KYTX) · Jul 9, 2026, 10:00 AM

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight · Jun 10, 2026, 5:15 PM

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? · Jun 8, 2026, 7:15 PM

HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target · Jun 3, 2026, 4:20 PM

Kyverna Therapeutics Appoints Greg Martini As CFO · May 18, 2026, 12:10 PM

Kyverna Therapeutics to Present at Upcoming Investor Conferences · May 14, 2026, 12:30 PM

JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29 · May 13, 2026, 3:34 PM

Kyverna Therapeutics Q1 EPS $(0.66) Beats $(0.73) Estimate · May 12, 2026, 8:40 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock